Revolution Medicines files 8-K covering a debt obligation
The biotech disclosed the filing under items 1.01 and 2.03 in a Form 8-K dated September 1, 2026.
Revolution Medicines, Inc., a Delaware-incorporated biological products company listed on Nasdaq under the tickers RVMD and RVMDW, filed a Form 8-K with the SEC on September 1, 2026.[1][2]
The filing, which carries accession number 0001193125-26-377362, reports a debt obligation and covers the period ending August 27, 2026.[1]
The 8-K was filed under items 1.01 and 2.03, with the matched document named rvmd-20260827.htm.[1]
The filing follows an executive departure at the company recorded on June 22, 2026.[3]